§ 01 Overview
Overview
Fixed combination of cagrilintide (amylin analog) and semaglutide, studied for additive weight loss in obesity and T2D.
REDEFINE Phase III program reported ~20–22% weight loss. Results fell short of some investor expectations.
§ 02 Mechanism
Mechanism of action
CagriSema combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide). The two mechanisms produce additive appetite suppression and gastric emptying delay.
- 01Additive weight loss vs. either monotherapy
- 02Improved metabolic markers
- 03Preserved lean mass in some trials
§ 03 Dosing
Dosing protocol
Standard Protocol
- Vial
- Combined vial
- BAC Water
- As per product
- Dose Range
- 2 – 6 mg weekly (cagri + sema)
- Route
- SubQ
- Frequency
- Weekly
- Cycle
- Titrate to target over several months.
§ 04 Evidence
Evidence & research
REDEFINE Phase III program reported ~20–22% weight loss. Results fell short of some investor expectations.
FDA Status
Investigational. Expected FDA filing late 2025 / 2026.
§ 05 Stacks
Common stacks
§ 06 News
In the news
8 articles from the last 12 months · updates hourly
Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials - Indian Pharma Post
Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials Indian Pharma Post
GLP-1, Amylin Analog Combo Cuts Blood Sugar, Weight in Diabetes Trials - MedPage Today
GLP-1, Amylin Analog Combo Cuts Blood Sugar, Weight in Diabetes Trials MedPage Today
Diabetes data bolster CagriSema ahead of obesity decision - The Pharma Letter
Diabetes data bolster CagriSema ahead of obesity decision The Pharma Letter
Novo Nordisk hits primary endpoints in phase 3 diabetes trials with CagriSema - medwatch.com
Novo Nordisk hits primary endpoints in phase 3 diabetes trials with CagriSema medwatch.com
CagriSema beats semaglutide on weight loss, HbA1c in type 2 diabetes trials - The Clinical Trial Vanguard
CagriSema beats semaglutide on weight loss, HbA1c in type 2 diabetes trials The Clinical Trial Vanguard
Novo Nordisk reports positive Phase 3 results for CagriSema in type 2 diabetes - marketscreener.com
Novo Nordisk reports positive Phase 3 results for CagriSema in type 2 diabetes marketscreener.com
Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications - PR Newswire
Once-Weekly CagriSema (Amylin-Semaglutide) Combination Injection More Effective than Standalone Medications PR Newswire
Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 - PR Newswire
Novo Nordisk's CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026 PR Newswire
§ 07 Sourcing
Sourcing & supply
Regulatory status
Investigational, no compounding path
Currently in active clinical trials. No compounding pathway. No brand product. The only US channels are RUO vendors that the FDA has targeted with warning letters. Assume any sourcing carries significant regulatory and quality risk.
No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.
Browse full supplier directory§ 09 Safety
Safety & side effects
Side effects
- 01Nausea can be more pronounced than either monotherapy
Contraindications
None specified.